Table 5.
Studies on therapeutic compounds in chemotherapeutic model
| Ref. | Compound | Time of administration | Species | Sex | Sample size1 | Dosage | Route | Test | Test day | Effect2 |
| Cetinkaya et al[91] | GM-CSF | Postoperative | Rat | N/A | 54 | 0.0503 | LO | BPR | 3 | ↑ 26 |
| Erdem et al[86] | GM-CSF | Postoperative | Rat | N/A | 30 | 0.0503 | LO | BPR | 3 | ↑ 98 |
| de Waard et al[87] | GM-CSF | Postoperative | Rat | M | 31 | 0.0053 | IP | BPR/BST | 7 | ↓ 35/NS |
| Interleukin-2 | 42 × 106 | SC | NS/NS | |||||||
| Bostanoğlu et al[88] | Iloprost | Postoperative | Rat | M | 38 | 0.0023 | N/A | BPR | 3/7 | ↑ 63/NS |
| Vasiliadis et al[90] | Iloprost | Postoperative | Rat | F | 34 | 0.0023 | IP | BPR | 5/8 | ↑ 44/NS |
| AL | ↓ 30/↓ 30 | |||||||||
| Zacharakis et al[89] | IGF-1 | Postoperative | Rat | M | 32 | 23 | IP | BPR/AL | 7 | ↑ 53/NS |
| Erenoğlu et al[84] | HBOT | Postoperative | Rat | M | 20 | BPR | 7 | ↑ 26 | ||
| 5Yildiz et al[85] | HBOT | Postoperative | Rat | F | 24 | BPR | 5 | NS |
1
Total number of animals;
2
↑% increase (P < 0.05) or ↓% decrease (P < 0.05) vs controls;
3
mg/kg;
4
IU/kg;
5
Chemoradiotherapy model. AL: Anastomotic leakage; BPR: Bursting pressure; BST: Breaking strength; F: Female; GM-CSF: Granulocyte macrophage-colony stimulating factor; HBOT: Hyperbaric oxygen therapy; IGF-1: Insulin-like growth factor-1; IP: Intraperitoneal; LO: Local; M: Male; N/A: Data not available; NS: Not statistically significant; SC: Subcutaneous.